Brief: Regulus Therapeutics Advances To Cohort 2 Of Phase 1B Multiple-Ascending Dose Clinical Trial Of Rgls8429 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
16/05/2023 14:49
May 16 (Reuters) - Regulus Therapeutics Inc RGLS.O :
* REGULUS THERAPEUTICS ADVANCES TO COHORT 2 OF PHASE 1B
MULTIPLE-ASCENDING DOSE (MAD) CLINICAL TRIAL OF RGLS8429 FOR THE
TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
(ADPKD)
* REGULUS THERAPEUTICS INC - BLINDED SAFETY DATA OBSERVED SO
FAR
ARE ENCOURAGING
Source text for Eikon: ID:nPn8LyF0ra
Further company coverage: RGLS.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Regulus Therapeutics
See all newsBrief: Novartis Completes Acquisition Of Regulus Therapeutics
Brief: Novartis Announces Expiration Of Hart-Scott-Rodino Waiting Period Of Regulus Therapeutics Tender Offer
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics
Regulus Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Regulus Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview